Pre-order Enquiry
Request Free Sample
Familial Chylomicronemia Syndrome (FCS)- Epidemiology Forecast to 2030
SKU ID : DEL-15560606 | Publishing Date : 01-Apr-2020 | No. of pages : 100
Request Sample
Request Customization
Check DiscountsDetailed TOC of Familial Chylomicronemia Syndrome (FCS)- Epidemiology Forecast to 2030
1. Key Insights2. Executive Summary of FCS
3. Familial Chylomicronemia Syndrome (FCS): Disease Background and Overview
3.1. Introduction
3.1.1. Signs and Symptoms of FCS
3.1.2. Genetics and Pathogenesis of FCS
3.2. Diagnosis of FCS
3.2.1. Diagnostic Algorithm
4. Epidemiology and Patient Population
4.1. Key Findings: 7MM
4.2. Assumptions and Rationale: 7MM
4.3. Total Prevalence of FCS in the 7MM
4.4. Total Diagnosed Prevalence of FCS in the 7MM
4.5. Age-specific Diagnosed Prevalence of FCS in the 7MM
5. United States
5.1. Total Prevalent cases of FCS in the United States
5.2. Total Diagnosed Prevalent cases of FCS in the United States
5.3. Severity- Specific Diagnosed Prevalence of FCS in the United States
5.4. Treated Patient Pool of FCS in the United States
6. EU-5 Country-wise Epidemiology
6.1. Germany
6.1.1. Total Prevalent cases of FCS in Germany
6.1.2. Total Diagnosed Prevalent cases of FCS in Germany
6.1.3. Severity- Specific Diagnosed Prevalence of FCS in Germany
6.1.4. Treated Patient Pool of FCS in Germany
6.2. France
6.2.1. Total Prevalent cases of FCS in France
6.2.2. Total Diagnosed Prevalent cases of FCS in France
6.2.3. Severity- Specific Diagnosed Prevalence of FCS in France
6.2.4. Treated Patient Pool of FCS in France
6.3. Italy
6.3.1. Total Prevalent cases of FCS in Italy
6.3.2. Total Diagnosed Prevalent cases of FCS in Italy
6.3.3. Severity-Specific Prevalence of FCS in Italy
6.3.4. Treated Patient Pool of FCS in Italy
6.4. Spain
6.4.1. Total Prevalent cases of FCS in Spain
6.4.2. Total Diagnosed Prevalent cases of FCS in Spain
6.4.3. Severity- Specific Diagnosed Prevalence of FCS in Spain
6.4.4. Treated Patient Pool of FCS in Spain
6.5. United Kingdom
6.5.1. Total Prevalent cases of FCS in the United Kingdom
6.5.2. Total Diagnosed Prevalent cases of FCS in the United Kingdom
6.5.3. Severity- Specific Diagnosed Prevalence of FCS in the United Kingdom
6.5.4. Treated Patient Pool of FCS in the United Kingdom
7. Japan
7.1. Total Prevalent cases of FCS in Japan
7.2. Total Diagnosed Prevalent cases of FCS in Japan
7.3. Severity- Specific Diagnosed Prevalence of FCS in Japan
7.4. Treated Patient Pool of FCS in Japan
8. Current Treatment Practices for FCS
8.1. Novel Therapies
8.2. Guidelines for FCS
8.3. Dietary Guidelines for all Patients with FCS
8.4. Dietary Guidelines by Population
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. Disclaimer
11. DelveInsight Capabilities
12. About DelveInsight
List of Figures, Tables and Charts Available in Familial Chylomicronemia Syndrome (FCS)- Epidemiology Forecast to 2030
Table 1 Summary of FCS Epidemiology, and Key Events (2017–2030)Table 2 Known Mutations Responsible for FCS
Table 3 Lipid Panel Parameters for Diagnosing FCS
Table 4 Major Sources Used
Table 5 Total prevalence of FCS in the 7MM (2017–2030)
Table 6 Total Diagnosed Prevalence of FCS in the 7MM (2017–2030)
Table 7 Age-specific Diagnosed Prevalence of FCS in the 7MM (2017–2030)
Table 8 Total Prevalent cases of FCS in the United States (2017–2030)
Table 9 Total Prevalent Cases of FCS in the United States (2017–2030)
Table 10 Severity- Specific Diagnosed Prevalence of FCS in the United States (2017–2030)
Table 11 Treated Patient Pool of FCS in the United States (2017–2030)
Table 12 Total Prevalent cases of FCS in Germany (2017–2030)
Table 13 Total Diagnosed Prevalent Cases of FCS in Germany (2017–2030)
Table 14 Severity- Specific Diagnosed Prevalence of FCS in Germany (2017–2030)
Table 15 Treated Patient Pool of FCS in Germany (2017–2030)
Table 16 Total Prevalent cases of FCS in France (2017–2030)
Table 17 Total Diagnosed Prevalent Cases of FCS in France (2017–2030)
Table 18 Severity- Specific Diagnosed Prevalence of FCS in France (2017–2030)
Table 19 Treated Patient Pool of FCS in France (2017–2030)
Table 20 Total Prevalent cases of FCS in Italy (2017–2030)
Table 21 Total Diagnosed Prevalent Cases of FCS in Italy (2017–2030)
Table 22 Severity-Specific Diagnosed Prevalence of FCS in Italy (2017–2030)
Table 23 Treated Patient Pool of FCS in Italy (2017–2030)
Table 24 Total Prevalent cases of FCS in Spain (2017–2030)
Table 25 Total Diagnosed Prevalent Cases of FCS in Spain (2017–2030)
Table 26 Severity-Specific Diagnosed Prevalence of FCS in Spain (2017–2030)
Table 27 Treated Patient Pool of FCS in Spain (2017–2030)
Table 28 Total Prevalent cases of FCS in the United Kingdom (2017–2030)
Table 29 Total Diagnosed Prevalent Cases of FCS in the United Kingdom (2017–2030)
Table 30 Severity-Specific Prevalence of FCS in the United Kingdom (2017–2030)
Table 31 Treated Patient Pool of FCS in the United Kingdom (2017–2030)
Table 32 Total Prevalent cases of FCS in Japan (2017–2030)
Table 33 Total Diagnosed Prevalent Cases of FCS in Japan (2017–2030)
Table 34 Severity- Specific Diagnosed Prevalence of FCS in Japan (2017–2030)
Table 35 Treated Patient Pool of FCS in Japan (2017–2030)
Table 36 Dietary and Treatment Guidelines for People with FCS throughout the Life Span
Figure 1 FCS SWOT Analysis
Figure 2 Signs and Symptoms of FCS
Figure 3 FCS Pathophysiology
Figure 4 Stepwise Approach to Identifying the Etiology of Severe Hypertriglyceridemia
Figure 5 A Practical Diagnostic Scoring System for FCS
Figure 6 Diagnostic Algorithm of FCS
Figure 7 Global Heat Map
Figure 8 Total prevalence of FCS in the 7MM (2017–2030)
Figure 9 Total Diagnosed Prevalence of FCS in the 7MM (2017–2030)
Figure 10 Age-specific Diagnosed Prevalence of FCS in the 7MM (2017–2030)
Figure 11 Total Prevalent cases of FCS in the United States (2017–2030)
Figure 12 Total Diagnosed Prevalent Cases of FCS in the United States (2017–2030)
Figure 13 Severity- Specific Diagnosed Prevalence of FCS in the United States (2017–2030)
Figure 14 Treated Patient Pool of FCS in the United States (2017–2030)
Figure 15 Total Prevalent cases of FCS in Germany (2017–2030)
Figure 16 Total Diagnosed Prevalent Cases of FCS in Germany (2017–2030)
Figure 17 Severity- Specific Diagnosed Prevalence of FCS in Germany (2017–2030)
Figure 18 Treated Patient Pool of FCS in Germany (2017–2030)
Figure 19 Total Prevalent cases of FCS in France (2017–2030)
Figure 20 Total Diagnosed Prevalent Cases of FCS in France (2017–2030)
Figure 21 Severity-Specific Prevalence of FCS in France (2017–2030)
Figure 22 Treated Patient Pool of FCS in France (2017–2030)
Figure 23 Total Prevalent cases of FCS in Italy (2017–2030)
Figure 24 Total Diagnosed Prevalent Cases of FCS in Italy (2017–2030)
Figure 25 Severity- Specific Diagnosed Prevalence of FCS in Italy (2017–2030)
Figure 26 Treated Patient Pool of FCS in Italy (2017–2030)
Figure 27 Total Prevalent cases of FCS in Spain (2017–2030)
Figure 28 Total Diagnosed Prevalent Cases of FCS in Spain (2017–2030)
Figure 29 Severity- Specific Diagnosed Prevalence of FCS in Spain (2017–2030)
Figure 30 Treated Patient Pool of FCS in Spain (2017–2030)
Figure 31 Total Prevalent cases of FCS in the United Kingdom (2017–2030)
Figure 32 Total Diagnosed Prevalent Cases of FCS in the United Kingdom (2017–2030)
Figure 33 Severity- Specific Diagnosed Prevalence of FCS in the United Kingdom (2017–2030)
Figure 34 Treated Patient Pool of FCS in in the United Kingdom (2017–2030)
Figure 35 Total Prevalent cases of FCS in Japan (2017–2030)
Figure 36 Total Diagnosed Prevalent Cases of FCS in Japan (2017–2030)
Figure 37 Severity- Specific Diagnosed Prevalence of FCS in Japan (2017–2030)
Figure 38 Treated Patient Pool of FCS in Japan (2017–2030)
